FDA grants Inovio accelerated approval for VOCERYQ in adult RRP
+2 new sources since this summary was written
On October 30, 2026, the U.S. Food and Drug Administration granted Inovio Pharmaceuticals accelerated approval for VOCERYQ, formerly INO-3107, to reduce surgery frequency in adults with recurrent respiratory papillomatosis. In the supporting RRP-001 efficacy population, 7 of 26 patients, or 27%, needed no papilloma excision during the 12 months after treatment. Inovio expects to begin making the therapy available in approximately 60 days and plans a full commercial launch in the first quarter of 2027.
Why it matters
The approval moves Inovio's first product toward commercialization and creates a potential nonsurgical treatment option for adults with RRP. Continued approval depends on verification of clinical benefit in a confirmatory study, so the regulatory status remains conditional.
Key facts
- 1VOCERYQ was approved for use with INOVIO's CELLECTRA 5PSP DNA-medicine delivery device. prnewswire.com
- 2The FDA requires INOVIO to submit a draft confirmatory-study protocol by the end of 2026, with final-protocol alignment expected by mid-2027. prnewswire.com
- 3INOVIO said it expects full field deployment during the first quarter of 2027. prnewswire.com
- 4The RRP-001 study enrolled 32 adults, and all 32 patients completed it. prnewswire.com
Open questions
- One report additionally attributes a decline in Precigen shares to competitive concerns, but that reaction is not corroborated by the other materials.
- One report also refers to an $80M court win alongside the FDA decision, but the court matter is not described in the primary approval material.
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.